Antidiabetic drug profile of COVID-19 patients with comorbid diabetes mellitus
DOI:
https://doi.org/10.46542/pe.2023.234.168172Keywords:
Antidiabetic, COVID-19, Diabetes, Drug profileAbstract
Background: Diabetes mellitus (DM) is a risk factor that can increase the severity and mortality of patients with COVID-19 infection. The use of antidiabetic drugs for diabetes mellitus patients with COVID-19 infection is very important to reduce these impacts.
Objective: This study aimed to determine the antidiabetic drug profiles of COVID-19 patients with comorbid diabetes mellitus.
Method: This study was an analytic cross-sectional electronic medical record data of patients diagnosed with COVID-19 and comorbid Diabetes Mellitus. It was carried out from May until December 2020.
Result: A total of 106 patients were involved and different types of antidiabetic drugs were used i.e., glimepiride in 32 patients (31.13%), metformin in 18 patients (16.98%), combination of long-acting and rapid-acting insulin in 20 patients (18.87%), and combination of metformin and glimepiride in 18 patients (16.98%).
Conclusion: The most commonly prescribed single antidiabetic therapy in patients with COVID-19 and comorbid diabetes mellitus was glimepiride, followed by glimepiride and metformin. The most common insulin therapy combination was long-acting and rapid-acting insulin.
References
Bailey, C.J., & Gwilt, M. (2022). Diabetes, metformin and the clinical course of Covid-19: Outcomes, mechanisms, and suggestions on the therapeutic use of metformin. Frontiers in Pharmacology, 13, 1–13. https://doi.org/10.3389/fphar.2022.784459
Bornstein, S.R., Rubino, F., Khunti, K., Mingrone, G., Hopkins, D., Birkenfeld, A.L., Boehm, B., Amiel, S., Holt, R.I., Skyler, J.S., DeVries, J.H., Renard, E., Eckel, R.H., Zimmet, P., Alberti, K.G., Vidal, J., Geloneze, B., Chan, J.C., Ji, L., & Ludwig, B. (2020). Practical recommendations for the management of diabetes in patients with COVID-19. The Lancet Diabetes and Endocrinology, 8(6), 546–550. Lancet Publishing Group. https://doi.org/10.1016/S2213-8587(20)30152-2
Bramante, C.T., Ingraham, N.E., Murray, T.A., Marmor, S., Hovertsen, S., Gronski, J., McNeil, C., Feng, R., Guzman, G., Abdelwahab, N., King, S., Tamariz, L., Meehan, T., Pendleton, K.M., Benson, B., Vojta, D., & Tignanelli, C.J. (2021). Metformin and risk of mortality in patients hospitalised with COVID-19: A retrospective cohort analysis. The Lancet Healthy Longevity, 2(1), e34–e41. https://doi.org/10.1016/S2666-7568(20)30033-7
Chee, Y.J., Tan, S.K., & Yeoh, E. (2020). Dissecting the interaction between COVID-19 and diabetes mellitus. Journal of Diabetes Investigation, 11(5), 1104–1114. Blackwell Publishing. https://doi.org/10.1111/jdi.13326
Chen, Y., Yang, D., Cheng, B., Chen, J., Peng, A., Yang, C., Liu, C., Xiong, M., Deng, A., Zhang, Y., Zheng, L., & Huang, K. (2020). Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care, 43(7), 1399–1407. https://doi.org/10.2337/dc20-0660
Corrao, S., Pinelli, K., Vacca, M., Raspanti, M., & Argano, C. (2021). Type 2 diabetes mellitus and COVID-19: A narrative review. Frontiers in Endocrinology, 12. https://doi.org/10.3389/fendo.2021.609470
Diniz Vilela, D., Gomes Peixoto, L., Teixeira, R.R., Belele Baptista, N., Carvalho Caixeta, D., Vieira De Souza, A., Machado, H.L., Pereira, M.N., Sabino-Silva, R., & Espindola, F.S. (2016). The role of metformin in controlling oxidative stress in muscle of diabetic rats. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2016/6978625
Dixon, A.E., & Peters, U. (2018). The effect of obesity on lung function. Expert Review of Respiratory Medicine, 12(9), 755–767. Taylor and Francis Ltd. https://doi.org/10.1080/17476348.2018.1506331
Jayanama, K., Srichatrapimuk, S., Thammavaranucupt, K., Kirdlarp, S., Suppadungsuk, S., Wongsinin, T., Nanthatanti, N., Phusanti, S., Pitidhammabhorn, D., & Sungkanuparph, S. (2021). The association between body mass index and severity of Coronavirus Disease 2019 (COVID-19): A cohort study. PLoS ONE, 16. https://doi.org/10.1371/journal.pone.0247023
Jung, C.-Y., Park, H., Dong, Kim, W., Lim, H., Jung, Chang, H., Yoon, Choi, J., Seong, Kim, W., & Chang, T.I. (2020). Association between body mass index and risk of COVID-19 : A Nationwide Case-Control Study in South Korea. Clinical Infectious Diseases, 73(7). https://doi.org/10.1093%2Fcid%2Fciaa1257
Kemkes RI. (2020). Keputusan Menteri Kesehatan Republik Indonesia No. HK.01.07/MenKes/413/2020 tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019. Regulasi. https://covid19.go.id/p/regulasi/keputusan-menteri-kesehatan-republik-indonesia-nomor-hk0107menkes4132020
Kimura, T., & Namkoong, H. (2020). Susceptibility of the obese population to COVID-19. International Journal of Infectious Diseases, 101, 380–381. https://doi.org/10.1016/j.ijid.2020.10.015
Koliaki, C., Tentolouris, A., Eleftheriadou, I., Melidonis, A., Dimitriadis, G., & Tentolouris, N. (2020). Clinical management of diabetes mellitus in the era of covid-19: Practical issues, peculiarities and concerns. Journal of Clinical Medicine, 9(7), 1–25. https://doi.org/10.3390/jcm9072288
Longo, M., Caruso, P., Maiorino, M.I., Bellastella, G., Giugliano, D., & Esposito, K. (2020). Treating type 2 diabetes in COVID-19 patients: The potential benefits of injective therapies. Cardiovascular Diabetology 19(115). https://doi.org/10.1186/s12933-020-01090-9
Satuan Tugas Penanganan COVID-19 (2021). Peta Sebaran COVID-19. Available at: https://covid19.go.id/peta-sebaran-covid19
Singh, A.K., Gupta, R., Ghosh, A., & Misra, A. (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(4), 303–310. https://doi.org/10.1016/j.dsx.2020.04.004
Singh, A.K., & Singh, R. (2020). Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? Diabetes Research and Clinical Practice, 165. Elsevier Ireland Ltd. https://doi.org/10.1016/j.diabres.2020.108268
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., Xu, L., Zhou, F., Jiang, J., Bai, C., Zheng, J., Song, Y. (2020). Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 180(7), 934–943. https://doi.org/10.1001/jamainternmed.2020.0994
Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. Clinical Immunology, 215. Academic Press Inc. https://doi.org/10.1016/j.clim.2020.108427
Zhu, L., She, Z.G., Cheng, X., Qin, J.J., Zhang, X.J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., Li, H., Zhang, P., Song, X., Chen, X., Xiang, M., Zhang, C., Bai, L., Xiang, D., Chen, M.M., Liu, Y., Yan, Y., Liu, M., Mao, W., Zou, J., Liu, L., Chen, G., Luo, P., Xiao, B., Zhang, C., Zhang, Lu, Z., Wang, J., Lu, H., Xia, X., Wang, D., Liao, X., Peng, G., Ye, P., Yang J., Yuan, Y., Huang, X.,
Guo J., Zhang, B.H., & Li, H. (2020). Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metabolism, 31(6), 1068-1077.e3. https://doi.org/10.1016/j.cmet.2020.04.021
